Full-Time
Market Research Manager
Posted on 8/20/2026
Alexion
5,001-10,000 employees
Global biopharmaceuticals focusing on rare diseases
No salary listed
Munich, Germany
In Person
Bachelor's, Master's
 Business & Strategy (1) |
|---|
Get referred to Alexion
See people who can refer or advise you
- A Master's or Bachelor's degree, or equivalent, is required.
- Work experience in healthcare or pharmaceutical market research, including the ability to design and manage quantitative and/or qualitative market research studies, is required.
- A deep understanding of market research approaches is required.
- Understanding of the use of artificial intelligence is required.
- The candidate must be able to interact frequently with external customers at various management levels and with functional peer groups.
- The candidate must be able to gain cooperation from others and present technical information concerning specific projects.
- Strong numerical and analytical skills and close attention to detail are required.
- Project management capabilities are required.
- The candidate must work collaboratively and flexibly to execute projects within a team environment and meet internal and external deadlines.
- Strong interpersonal skills are required.
- The candidate must be motivated and able to demonstrate initiative.
- An interest in consulting, healthcare, and the pharmaceutical industry is required.
- Lead and coordinate qualitative and quantitative primary and secondary market research studies in line with the needs of the Marketing and Sales departments.
- Develop market intelligence capabilities within the Sales and Marketing organization.
- Serve as an expert with professional knowledge of relevant market research data and databases, including IQVIA and other sources.
- Analyze, evaluate, and monitor the market positioning of Alexion and competitor products.
- Identify market and company trends and articulate how they translate into growth opportunities for clients.
- Generate reports of findings and present them to senior management and brand teams.
- Provide Sales Leadership and Marketing Leadership with meaningful insights and best practices across indications and teams.
- Develop effective business intelligence strategies and analytics solutions in partnership with Marketing.
- Analyze consumer preferences to determine the potential sales of products or services.
- Partner with Global and International teams to define needs and projects.
- Support global market research projects and incorporate German needs and perspectives.
- Partner with relevant functions to ensure all perspectives and needs are included and improve outcomes and impact.
- Ensure a high level of expertise and excellence in customer service is delivered to customers.
- Work professionally and in accordance with the company's Code of Ethics and Business Conduct.
- Report pharmacovigilance information according to Alexion procedures.
- Ability to attend, understand, and participate in international meetings conducted in English.
Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1992
Get referred to Alexion
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ultomiris received FDA priority review June 15, 2026 for IgA nephropathy.
- Alexion advanced ALXN2220 into phase 3 for ATTR-CM on April 10, 2026.
- AAN 2026 data highlighted gefurulimab, Koselugo, and Ultomiris across neurology indications.
What critics are saying
- Epysqli, a Soliris biosimilar, won FDA approval July 22, 2026, crushing legacy margins.
- Strensiq successor efzimfotase alfa missed the adult primary endpoint in March 2026.
- Alexion remains exposed to Ultomiris concentration; one setback hits hematology, nephrology, and neurology growth.
What makes Alexion unique
- Alexion built first-mover complement biology expertise and still leads C5 inhibition.
- AstraZeneca gives Alexion global scale, capital, and regulatory reach in rare disease.
- Its portfolio spans Soliris, Ultomiris, Strensiq, Kanuma, and emerging antibody modalities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Stock Options
Company Equity
401(k) Retirement Plan
Mental Health Support
Wellness Program
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Training Programs
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Relocation Assistance
Employee Referral Bonus
Meal Benefits
Commuter Benefits
Legal Services
Employee Discounts
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."
Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM. Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM
WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”
WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2
Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease. . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old